1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTargeting Brain Cell Subtypes in Aging and AD/ADRD (R61/R33 Clinical Trial Not Allowed) is sponsored by National Institute on Aging (NIA). This funding opportunity invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
You are using an outdated browser. Please upgrade your browser to improve your experience. BSR has recently published or joined the following new Requests for Applications (RFAs), Program Announcements (PARs), Notices of Special Interest (NOSIs), and Requests for Information (RFIs): NEW!
RFA-AG-25-029: Short Courses on Utilizing the NIH Stage Model to Develop Behavioral Interventions to Promote Healthy Aging (R25 – Independent Clinical Trial Not Allowed) . Applications due October 8, 2024. NEW!
RFA-AG-25-025: Short Courses Promoting Cross-National Analyses Using Data from the International Health and Retirement Study (HRS) and Harmonized Cognitive Assessment Protocol (HCAP) (R25 Clinical Trial Not Allowed) . Applications due November 1, 2024. NEW!
RFA-AG-25-019: The Impact of Stressors on the Biological Mechanisms of Aging and Other Aging-Associated Outcomes in Experimental Model Systems (R61/R33 Clinical Trial Not allowed) . Applications due November 7, 2024. NEW!
RFA-AG-25-031 : Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed). Applications due November 7, 2024. NEW!
RFA-AG-25-032: Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed). First application due date November 7, 2024. NEW!
NOT-MH-24-365 : Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) . First estimated application due date June 13, 2025. NEW!
RFA-AT-25-001: HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) . Multiple receipt dates through October 27, 2026. NEW!
PAR-24-271: NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) . Multiple receipt dates through June 12, 2027. NEW!
PAR-24-273: Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 – Clinical Trial Optional) . Multiple receipt dates through January 7, 2028. NEW!
NOT-OD-24-169: Updating the Definition of Sexual and Gender Minority Populations in NIH-Supported Research.
According to the current listing, eligibility includes: Other eligible applicants include: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; …. Confirm the full requirements in the official notice before applying.
Targeting Brain Cell Subtypes in Aging and AD/ADRD (R61/R33 Clinical Trial Not Allowed) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Alaska. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article